Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, B. Yа. Alekseev, Francis Parnis, Vagif Atduev, Gary L. Buchschacher, Rustem Gafanov, Luis Corrales, Michael Borre, Daniil Stroyakovskiy, Gustavo Vasconcelos Alves, Evangelos Bournakis, Javier Puente, Marie-Laurence Harle-Yge, Jorge D. Gallo, Geng Chen, Justin Hanover, Matthew Wongchenko, Josep Garcia, Johann S. de Bono
Topics & Concepts
MedicineProstate cancerAbirateronePrednisoloneDouble blindAbiraterone acetateOncologyCastrationInternal medicineUrologyCancerAndrogen deprivation therapyPlaceboHormonePathologyAlternative medicineAndrogen receptorProstate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancerProstate Cancer Diagnosis and Treatment